Donanemab (Kisunla)

Donanemab (Kisunla)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Donanemab (Kisunla)</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>N3pG-Aβ (pyroglutamate)</td>
</tr>
<tr>
<td class="label">[Lecanemab](/therapeutics/lecanemab)</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Multiple Aβ forms</td>
</tr>
<tr>
<td class="label">Tau Level</td>
<td>CDR-SB Benefit</td>
</tr>
<tr>
<td class="label">Low/Medium</td>
<td>Greater benefit</td>
</tr>
<tr>
<td class="label">High</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">Brain amyloid (Centiloid)</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Slower accumulation in low-tau group</td>
</tr>
<tr>
<td class="label">ARIA Type</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>~24%</td>
</tr>
<tr>
<td class="label">ARIA-H (hemorrhage)</td>
<td>~7%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N3pG-Aβ plaques</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>350 mg q4w</td>
</tr>
<tr>
<td class="label">Treatment approach</

...

Donanemab (Kisunla)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Donanemab (Kisunla)</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>N3pG-Aβ (pyroglutamate)</td>
</tr>
<tr>
<td class="label">[Lecanemab](/therapeutics/lecanemab)</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Multiple Aβ forms</td>
</tr>
<tr>
<td class="label">Tau Level</td>
<td>CDR-SB Benefit</td>
</tr>
<tr>
<td class="label">Low/Medium</td>
<td>Greater benefit</td>
</tr>
<tr>
<td class="label">High</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">Brain amyloid (Centiloid)</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Slower accumulation in low-tau group</td>
</tr>
<tr>
<td class="label">ARIA Type</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>~24%</td>
</tr>
<tr>
<td class="label">ARIA-H (hemorrhage)</td>
<td>~7%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N3pG-Aβ plaques</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>350 mg q4w</td>
</tr>
<tr>
<td class="label">Treatment approach</td>
<td>Limited duration</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>~24%</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>~0.70</td>
</tr>
</table>

Introduction

Donanemab (Kisunla) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

[Donanemab](/entities/donanemab) (brand name Kisunla) is an intravenous monoclonal antibody approved in the United States for treatment of early symptomatic [Alzheimer's disease](/diseases/alzheimers-disease) in adults with confirmed [amyloid-beta](/proteins/amyloid-beta) pathology[@fda2024][@sims2023]. It is an IgG1 antibody that preferentially binds pyroglutamate-modified [amyloid-beta](/proteins/amyloid-beta) (N3pG-Aβ), an epitope enriched in deposited plaques rather than soluble monomeric peptide[@ovod2017].

Clinically, donanemab belongs to the same disease-modifying anti-amyloid class as [Lecanemab (Leqembi)](/therapeutics/lecanemab), but differs in epitope preference, treatment-stopping rules based on plaque clearance, and trial stratification by baseline [tau](/proteins/tau) burden[@sims2023][@mintun2021].

Mechanism of Action

Target Specificity

Donanemab's key mechanism differs from other anti-amyloid antibodies:

• Pyroglutamate Aβ targeting: Binds specifically to N3pG-Aβ, a modification found in mature plaques
• Plaque-selective binding: Prefers deposited plaques over soluble monomers
• Fc-mediated clearance: Triggers microglial phagocytosis through Fcγ receptor engagement
• Rapid plaque reduction: Achieves substantial amyloid clearance within months

Epitope Differences

Clinical Development

Phase 2: TRAILBLAZER-ALZ

The Phase 2 TRAILBLAZER-ALZ trial enrolled 272 patients with early AD[@mintun2021]:

• Primary endpoint: Change in Integrated Alzheimer's Disease Rating Scale (iADRS) at 76 weeks
• Result: Significant plaque reduction and modest slowing of cognitive decline vs. placebo
• Key finding: Established concept of biomarker-guided discontinuation after amyloid clearance

This trial pioneered the approach of stopping treatment once amyloid plaques are cleared, potentially reducing treatment burden and ARIA risk.

Phase 3: TRAILBLAZER-ALZ 2

The Phase 3 TRAILBLAZER-ALZ 2 trial enrolled 1,736 patients with early AD[@sims2023]:

• Primary endpoint: Change in CDR-SB at 18 months
• Results: Statistically significant slowing of clinical progression
• Amyloid reduction: Marked reduction meeting pre-specified thresholds
• [Tau](/proteins/tau) stratification: Participants divided into low/medium and high tau groups

Subgroup Analysis by Tau Burden

The results support earlier intervention in the disease process when there is less established tau pathology.

Efficacy

Cognitive Outcomes

• Reduced clinical decline on multiple cognitive measures
• Benefits observed across CDR-SB, ADAS-Cog13, and ADCS-iADL
• Greater benefit in participants with lower baseline tau

Biomarker Effects

Safety Profile

Amyloid-Related Imaging Abnormalities (ARIA)

• Most cases mild to moderate
• Incidence highest in first 12 weeks
• Monitoring with MRI required

Management

Monitoring Protocol:

• Baseline MRI before first infusion
• MRI at Week 12, Week 24, then as clinically indicated
• [APOE](/proteins/apoe-protein) ε4 carriers require closer monitoring
• Hold treatment for moderate-severe ARIA

Other Adverse Events

• Infusion-related reactions
• Generally manageable with standard protocols

Treatment Approach: Limited-Duration Therapy

Donanemab represents a paradigm shift with limited-duration treatment:

Initial intensive treatment: Monthly infusions for ~18 months

Assessment for discontinuation: [Amyloid PET](/entities/amyloid-pet) or CSF testing

Treatment stop: If amyloid cleared below threshold

Monitoring: Continued observation off treatment

This approach may:

• Reduce cumulative ARIA risk
• Lower treatment costs
• Improve patient convenience

Regulatory Status

Approvals

• United States: FDA approved (July 2024)
• Other regions: Under review

Indication

Early Alzheimer's Disease (MCI due to AD or mild dementia) with confirmed amyloid pathology.

Comparison with Other Anti-Amyloid Therapies

Future Directions

Combination Approaches

• Combination with tau-targeting agents
• Earlier intervention in preclinical AD
• Personalized treatment based on biomarker profiles

Ongoing Studies

• TRAILBLAZER-ALZ 3: Prevention trial
• TRAILBLAZER-ALZ 4: Imaging outcomes
• Long-term safety extensions

AAIC 2026 Updates

For comprehensive coverage of donanemab data presented at AAIC 2026, including new analyses on amyloid removal rates, subpopulation responses, TRAILBLAZER-ALZ 3 prevention trial updates, and long-term outcomes following limited-duration treatment, see: [AAIC 2026: Immunotherapy and Antibody Therapeutics Update](/events/aaic-2026/immunotherapy-update)

Background

The study of Donanemab (Kisunla) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Lecanemab](/entities/lecanemab)
• [Aducanumab](/therapeutics/aducanumab)
• Anti-Amyloid Immunotherapy

External Links

• [Kisunla Official Website](https://www.kisunla.com)
• [ClinicalTrials.gov: Donanemab](https://clinicaltrials.gov/search?term=Donanemab)
• [Lilly Neuroscience](https://www.lilly.com)

References

FDA. (2024). Donanemab (Kisunla) Prescribing Information, https://www.fda.gov (2024)

[Sims, J.R., et al. (2023). Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2303370 (2023)](https://doi.org/10.1056/NEJMoa2303370](https://doi.org/10.1056/NEJMoa2303370](https://doi.org/10.1056/NEJMoa2303370)

[Ovod, V., et al. (2017). Amyloidloidogen. Nature Neuroscience, https://doi.org/10.1038/nn.4587 (2017)](https://doi.org/10.1038/nn.4587](https://doi.org/10.1038/nn.4587](https://doi.org/10.1038/nn.4587)

[Mintun, M.A., et al. (2021). Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2100708 (2021)](https://doi.org/10.1056/NEJMoa2100708](https://doi.org/10.1056/NEJMoa2100708](https://doi.org/10.1056/NEJMoa2100708)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE

Related Analyses:

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;